US biotech COUR Pharma has closed a $50 million series B financing round to advance CNP-103, its experimental type 1 diabetes therapy designed to address the autoimmune cause of the disease rather ...
CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results